Omalizumab (Xolair): an anti-IgE antibody for asthma.
D000293:Adolescent; D000328:Adult; D000707:Anaphylaxis / Q000209:etiology; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D004311:Double-Blind Method; D005252:Fees, Pharmaceutical; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007279:Injections, Subcutaneous; D000069444:Omalizumab; D016032:Randomized Controlled Trials as Topic; D006255:Rhinitis, Allergic, Seasonal
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab; D007073:Immunoglobulin E